Key result
Anti-periostin antibody improved post-SAH neurobehavior, brain edema, and blood-brain barrier disruption, whereas recombinant periostin aggravated post-SAH brain edema.
Why the study?
Does anti-periostin antibody or recombinant periostin alter early brain injury after subarachnoid hemorrhage in a mouse model?
RCT (n=235)
Blinded
Randomized
Does anti-periostin antibody or recombinant periostin alter early brain injury after subarachnoid hemorrhage in a mouse model?
Inhibition of periostin attenuates early brain injury after subarachnoid hemorrhage in mice, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Periostin inhibition attenuates experimental post-SAH injury; leaves open translation to human early brain injury.
BACKGROUND AND PURPOSE: A matricellular protein tenascin-C is implicated in early brain injury after experimental subarachnoid hemorrhage (SAH). This study first evaluated the role of another matricellular protein periostin and the relationships with tenascin-C in post-SAH early brain injury. METHODS: Wild-type (n=226) and tenascin-C knockout (n=9) C57BL/6 male adult mice underwent sham or filament perforation SAH modeling. Vehicle, anti-periostin antibody, or recombinant periostin was randomly administrated by an intracerebroventricular injection at 30 minutes post-modeling. Neuroscores, SAH grading, brain water content, immunostaining, and Western blotting were blindly evaluated at 24 to 48 hours post-SAH. RESULTS: Periostin was induced in brain capillary endothelial cells and neurons at 24 hours post-SAH. Anti-periostin antibody improved post-SAH neurobehavior, brain edema, and blood-brain barrier disruption associated with downregulation of tenascin-C, inactivation of p38, extracellular signal-related kinase 1/2 and matrix metalloproteinase-9, and subsequent preservation of zona occludens-1. Recombinant periostin aggravated post-SAH brain edema and tenascin-C induction. Tenascin-C knockout prevented post-SAH neurobehavioral impairments and periostin induction. CONCLUSIONS: Periostin may cause post-SAH early brain injury through activating downstream signaling pathways and interacting with tenascin-C, providing a novel approach for the treatment of early brain injury.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) conducted an RCT in Subarachnoid Hemorrhage (n=235). Anti-periostin antibody or recombinant periostin vs. Vehicle was evaluated on Neuroscores, SAH grading, brain water content, immunostaining, and Western blotting. Anti-periostin antibody improved post-SAH neurobehavior, brain edema, and blood-brain barrier disruption, whereas recombinant periostin aggravated post-SAH brain edema.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: